Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

919 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma.
Mohlin S, Hansson K, Radke K, Martinez S, Blanco-Apiricio C, Garcia-Ruiz C, Welinder C, Esfandyari J, O'Neill M, Pastor J, von Stedingk K, Bexell D. Mohlin S, et al. Among authors: pastor j. EMBO Mol Med. 2019 Aug;11(8):e10058. doi: 10.15252/emmm.201810058. Epub 2019 Jul 16. EMBO Mol Med. 2019. PMID: 31310053 Free PMC article.
Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR.
Martínez González S, Hernández AI, Varela C, Lorenzo M, Ramos-Lima F, Cendón E, Cebrián D, Aguirre E, Gomez-Casero E, Albarrán MI, Alfonso P, García-Serelde B, Mateos G, Oyarzabal J, Rabal O, Mulero F, Gonzalez-Granda T, Link W, Fominaya J, Barbacid M, Bischoff JR, Pizcueta P, Blanco-Aparicio C, Pastor J. Martínez González S, et al. Among authors: pastor j. Bioorg Med Chem Lett. 2012 Aug 15;22(16):5208-14. doi: 10.1016/j.bmcl.2012.06.093. Epub 2012 Jul 4. Bioorg Med Chem Lett. 2012. PMID: 22819764
Identification of novel PI3K inhibitors through a scaffold hopping strategy.
Martínez González S, Hernández AI, Álvarez RM, Rodríguez A, Ramos-Lima F, Bischoff JR, Albarrán MI, Cebriá A, Hernández-Encinas E, García-Arocha J, Cebrián D, Blanco-Aparicio C, Pastor J. Martínez González S, et al. Among authors: pastor j. Bioorg Med Chem Lett. 2017 Nov 1;27(21):4794-4799. doi: 10.1016/j.bmcl.2017.09.059. Epub 2017 Sep 30. Bioorg Med Chem Lett. 2017. PMID: 29017786
Multiple cancer pathways regulate telomere protection.
Bejarano L, Bosso G, Louzame J, Serrano R, Gómez-Casero E, Martínez-Torrecuadrada J, Martínez S, Blanco-Aparicio C, Pastor J, Blasco MA. Bejarano L, et al. Among authors: pastor j. EMBO Mol Med. 2019 Jul;11(7):e10292. doi: 10.15252/emmm.201910292. Epub 2019 Jun 13. EMBO Mol Med. 2019. PMID: 31273934 Free PMC article.
Omipalisib inspired macrocycles as dual PI3K/mTOR inhibitors.
Álvarez RM, García AB, Riesco-Fagundo C, Martín JI, Varela C, Rodríguez Hergueta A, González Cantalapiedra E, Oyarzabal J, Di Geronimo B, Lorenzo M, Albarrán MI, Cebriá A, Cebrián D, Martínez-González S, Blanco-Aparicio C, Pastor J. Álvarez RM, et al. Among authors: pastor j. Eur J Med Chem. 2021 Feb 5;211:113109. doi: 10.1016/j.ejmech.2020.113109. Epub 2020 Dec 18. Eur J Med Chem. 2021. PMID: 33360802
Macrocyclization as a Source of Desired Polypharmacology. Discovery of Triple PI3K/mTOR/PIM Inhibitors.
Martínez-González S, Alvarez RM, Martín JI, García AB, Riesco-Fagundo C, Varela C, Rodríguez Hergueta A, González Cantalapiedra E, Albarrán MI, Gómez-Casero E, Cebriá A, Aguirre E, Ajenjo N, Cebrián D, Di Geronimo B, Cunningham D, O'Neill M, Dave HPG, Blanco-Aparicio C, Pastor J. Martínez-González S, et al. Among authors: pastor j. ACS Med Chem Lett. 2021 Nov 2;12(11):1794-1801. doi: 10.1021/acsmedchemlett.1c00412. eCollection 2021 Nov 11. ACS Med Chem Lett. 2021. PMID: 34795869 Free PMC article.
Modulation of telomere protection by the PI3K/AKT pathway.
Méndez-Pertuz M, Martínez P, Blanco-Aparicio C, Gómez-Casero E, Belen García A, Martínez-Torrecuadrada J, Palafox M, Cortés J, Serra V, Pastor J, Blasco MA. Méndez-Pertuz M, et al. Among authors: pastor j. Nat Commun. 2017 Nov 2;8(1):1278. doi: 10.1038/s41467-017-01329-2. Nat Commun. 2017. PMID: 29097657 Free PMC article.
The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status.
Trigg RM, Lee LC, Prokoph N, Jahangiri L, Reynolds CP, Amos Burke GA, Probst NA, Han M, Matthews JD, Lim HK, Manners E, Martinez S, Pastor J, Blanco-Aparicio C, Merkel O, de Los Fayos Alonso IG, Kodajova P, Tangermann S, Högler S, Luo J, Kenner L, Turner SD. Trigg RM, et al. Among authors: pastor j. Nat Commun. 2019 Nov 28;10(1):5428. doi: 10.1038/s41467-019-13315-x. Nat Commun. 2019. PMID: 31780656 Free PMC article.
Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition.
Blanco-Aparicio C, Collazo AM, Oyarzabal J, Leal JF, Albarán MI, Lima FR, Pequeño B, Ajenjo N, Becerra M, Alfonso P, Reymundo MI, Palacios I, Mateos G, Quiñones H, Corrionero A, Carnero A, Pevarello P, Lopez AR, Fominaya J, Pastor J, Bischoff JR. Blanco-Aparicio C, et al. Among authors: pastor j. Cancer Lett. 2011 Jan 28;300(2):145-53. doi: 10.1016/j.canlet.2010.09.016. Epub 2010 Nov 3. Cancer Lett. 2011. PMID: 21051136
919 results